Navigation Links
Kiwa Posts Video of 2007 Annual Management Meetings

BEIJING and CLAREMONT, Calif., Jan. 21 /Xinhua-PRNewswire-FirstCall/ -- Kiwa Bio-Tech Products Group Corporation (OTC Bulletin Board: KWBT) has posted a video of portions of the recently completed and announced annual management meetings including year-end business review, planning for 2008 and employee recognition ceremonies.

Highlights include presentations by senior managers:

Mr. Zhang, Director and General Manager of Kiwa Shandong: "We have completed equipment installation and the first phase of bacillus fermentation technology upgrade. Currently, the principal part of the project has been accomplished and we are successfully producing fertilizers."

Mr. Wenbin Li, Vice President of Kiwa Tianjin: "Based on the operational results of 2007, we have set the operating target for 2008. We plan to sell various bio-feeds of 40,000 tons in total, including pig feeds 5,000 tons (about 12.5% of the total amount), feeds for chickens, ducks and other foul of 25,000 tons (about 62.5% of the total amount), fish feeds 5,000 tons (about 12.5% of the total amount) and cow feeds 5,000 tons (about 12.5% of the total amount)."

Prof. Wang, Professor of CAU (China Agricultural University), Director of Kiwa-CAU R & D Center and Director of the Company: "Through 2007, Kiwa-CAU R & D Center has mainly concentrated on the researching and development of bio- fertilizers and bio-feeds."

Mr. Song, Marketing and Sales director of the Company: "Currently, supporting the factory in Shandong, we have constructed a distribution network organization which includes 900 terminals within 4 areas in the south of Hebei. We are also actively negotiating to expand to Neimeng, Jilin, Heilongjiang and Suzhou. These areas basically fit in our distribution network building plan."

Mr. Wei Li, Chairman of the Board and CEO of the Company: "We signed a Letter of Intent with Shijiazhuang Huaxing Animal Medicine Co., Ltd. ("Huaxing") in December, 2007 and now are in the due diligence investigation stage. Along with the acquisition of the factory that produces pharmaceuticals with GMP (Good Manufacturing Process), Kiwa's objective is to offer three main divisions of agricultural products. We expect to realize this objective in the near future."

To see the video please see:

About Kiwa Bio-Tech Products Group Corporation

The Company develops, manufactures, distributes and markets innovative, cost-effective, and environmentally safe bio-technological products for agricultural and natural resources and environmental conservation. The Company has acquired the rights to manufacture and market AF-01 Anti-viral Aerosol Agent for use in preventing (blocking) bird-flu disease in Chinese and international markets. The Company has excellent relations with government authorities in China and has developed several innovative, high margin products, while continuing to grow through internal and external product development. The Company's products are designed to enhance the quality of human life by increasing the value, quality and productivity of crops and decreasing the negative environmental impact of chemicals and other wastes. For more information about the Company, please review documents filed with the SEC ( ) or visit the Company's website at .

This press release contains information that constitutes forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any such forward-looking statements involve risk and uncertainties that could cause actual results to differ materially from any future results described by the forward-looking statements. Risk factors that could contribute to such differences include those matters more fully disclosed in the Company's reports filed with the Securities and Exchange Commission. The forward-looking information provided herein represents the Company's estimates as of the date of the press release, and subsequent events and developments may cause the Company's estimates to change. The Company specifically disclaims any obligation to update the forward- looking information in the future. Therefore, this forward-looking information should not be relied upon as representing the Company's estimates of its future financial performance as of any date subsequent to the date of this press release.

For more informtion, please contact:

Kiwa Bio-Tech Products Group Corporation

Yvonne Wang

Tel: +1-626-715-5855


Robert Schechter

Equity Communications

Tel: +1-212-499-6809


SOURCE Kiwa Bio-Tech Products Group Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. National Stem Cell Holding, Inc. Posts Company and Financial Information on the OTCIQ and Has Retained New CFO and Counsel to File Registration Statement With SEC
2. Video and Photo: Tekturna HCT(R), a Single-tablet Combination of Tekturna(R)* and a Diuretic, Receives US Approval for Treatment of High Blood Pressure
3. MultiVu Video Feed: Easypod(R), Award-Winning Electronic Device
4. Video and Photo: EMD Serono Launches easypod(R), New Electronic Growth Hormone Injection Device
5. Video shows buckyballs form by shrink wrapping
6. Video: New Survey Finds Technology Plays a Critical Role in Lives of People with Multiple Sclerosis, Yet Many Are Not Using it to Overcome Disease-Related Challenges
7. Video: Trinity Mother Frances Neurosurgeon Using New Disc System for Patients With Degenerative Diseases of the Neck
8. MultiVu Video Feed: Hard Rocks 2007 Ambassadors of Rock Tour Is "On the Road Again" With Music Legend Willie Nelson
9. MultiVu Video Feed: Allergan, Inc. Partners With "Project Runway" Designer Kara Saun and Gen Art Fresh Faces In Fashion to Raise Awareness About Excessive Underarm Sweating
10. Kiwa Holds 2007 Annual Management Meetings and Employee Recognition Ceremonies in Beijing
11. Kensey Nash to Participate in the Sidoti Fifth Annual Palm Beach Emerging Growth Institutional Investor Forum Conference
Post Your Comments:
(Date:11/25/2015)... , Nov. 25, 2015  PharmAthene, Inc. (NYSE ... has adopted a stockholder rights plan (Rights Plan) in ... operating loss carryforwards (NOLs) under Section 382 of the ... --> PharmAthene,s use of its NOLs could ... change" as defined in Section 382 of the Code. ...
(Date:11/25/2015)... -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today ... Neurocrine Biosciences, will be presenting at the 27th Annual ... . .   Listeners ... prior to the presentation to download or install any ... available on the website approximately one hour after the ...
(Date:11/25/2015)... 25, 2015 The Global ... a professional and in-depth study on the current ... (Logo: ) , The ... including definitions, classifications, applications and industry chain structure. ... international markets including development trends, competitive landscape analysis, ...
(Date:11/24/2015)... Cepheid (NASDAQ: CPHD ) today announced ... conference, and invited investors to participate via webcast. ... December 1, 2015 at 11.00 a.m. Eastern Time ... December 1, 2015 at 11.00 a.m. Eastern Time ... York, NY      Tuesday, December 1, 2015 at ...
Breaking Biology Technology:
(Date:10/29/2015)... Mich. , Oct. 29, 2015  Rubicon ... Genomics for U.S. distribution of its DNA library ... kit and Rubicon,s new ThruPLEX Plasma-seq kit. ThruPLEX ... enable the preparation of NGS libraries for liquid ... for diagnostic and prognostic applications in cancer and ...
(Date:10/27/2015)... 27, 2015 In the present market scenario, ... for various industry verticals such as banking, healthcare, defense, ... growing demand for secure & simplified access control and ... as hacking of bank accounts, misuse of users, , ... as PC,s, laptops, and smartphones are expected to provide ...
(Date:10/26/2015)... and LAS VEGAS , Oct. 26, ... , an innovator in modern authentication and a founding ... the launch of its latest version of the Nok ... organizations to use standards-based authentication that supports existing and ... Authentication Suite is ideal for organizations deploying customer-facing applications ...
Breaking Biology News(10 mins):